Video Experimental Relacionado

Updated: Jun 10, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Análisis retrospectivo del impacto de los antidepresivos con actividad antiacida de la esfingomielinasas en la

Cindy M Liu1, Luiz Henrique Medeiros Geraldo2, Julie Xiao3

  • 1New York University (NYU) Grossman School of Medicine, New York, NY, USA.

Journal of neuro-oncology
|January 3, 2026
PubMed
Resumen

No abstract available in PubMed .

Palabras clave:
Inhibidor de la esfingomielinasa ácidaFluoxetina y sus derivadosEl glioblastoma

Más Videos Relacionados

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

7.2K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.2K

Videos de Conceptos Relacionados

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.